Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World April 9, 2015 Emma Stoye	BMS invests in gene therapy Bristol-Myers Squibb has agreed to invest over $100 million in Netherlands-based biotechnology company uniQure, which specializes in gene therapies for cardiovascular diseases.
The Motley Fool March 3, 2011 Ryan McBride	With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players.
Managed Care September 2004 Thomas Morrow	Orphan Drug Act Treatments Deserve Full Insurance Coverage An important federal law encourages development of drugs for populations so small that the market would otherwise ignore them. Should they not then be covered?
The Motley Fool June 3, 2010 Brian Orelli	When All Else Fails, Sue Your Competitors Biogen thinks its patent covers its competitors' drugs in addition to Avonex and has filed a lawsuit demanding royalties from its competitors.
The Motley Fool September 21, 2006 Brian Lawler	Another Partner for Biogen The pharmaceutical enlists help to thwart a troublesome illness. After the market closed yesterday, Biogen added another collaboration agreement with Alnylam Pharmaceuticals to its long list of partners. Investors, take note.
Managed Care February 2005 Mark Zitter	Managing Drugs for Rare Genetic Diseases: Trends and Insights Evaluates recent trends and challenges in health system management of exceedingly rare genetic diseases, from the perspective of the manufacturer, managed care organization, physician, and actuary.
The Motley Fool March 10, 2010 Brian Orelli	You Paid How Much for That? Abbott steps up where Biogen Idec wouldn't.
Chemistry World February 24, 2010 James Urquhart	Buckyball-based gene delivery Japanese researchers have demonstrated effective gene delivery in mice using carbon buckyballs.
The Motley Fool December 4, 2009 Brian Orelli	Our Final Offer (Maybe)! That's a FACT! Biogen ups its bid for Facet.
The Motley Fool December 13, 2007 Brian Lawler	Biogen Can't Find a Buyer After formally putting itself up for sale two months ago, Biogen Idec announces that it can't find any takers.
The Motley Fool July 23, 2008 Brian Lawler	No Picking at Biogen At a time in which all of its top drugs experienced at least double-digit percentage sales growth, there aren't many issues to poke at with Biogen Idec's just-released second-quarter financial results.
The Motley Fool December 21, 2004 Charly Travers	Invest With Fewer Side Effects Averse to risk? Check out these nontraditional drug companies: Biogen Idec... Elan... Salix Pharmaceuticals... Atrix Laboratories... etc.
The Motley Fool July 30, 2007 Brian Orelli	Another Blow to Gene Therapy The FDA shuts down a clinical trial, tripping up Targeted Genetics and possibly its competitors. A subject in the trial of their gene therapy arthritis medication died shortly after taking the drug.
The Motley Fool June 30, 2010 Ryan McBride	Reports: Biogen Picks Exelixis Chief George Scangos as New CEO George Scangos, a microbiologist by training, has been CEO of the South San Francisco-based cancer drug developer Exelixis since 1996, and takes over at Biogen immediately.
Chemistry World November 5, 2012 Andrew Turley	Approval for first gene therapy drug Alipogene tiparvovec, marketed as Glybera, has become the first gene therapy drug to win approval in either the US or the EU.
The Motley Fool June 8, 2010 Ryan McBride	Biogen's CEO Retires, COO to Follow A replacement won't be announced for a few weeks.
BusinessWeek April 22, 2010 Rob Waters	Gene Therapy Takes a Turn for the Better Researchers and investors are heartened by advances in gene therapy. Analysts say revenues are still several years off, however.
The Motley Fool September 4, 2009 Brian Orelli	Takeover Likely? Management Says No! A hostile bid that management didn't want. Biogen Idec announced today that it's willing to buy Facet Biotech for $14.50 per share.
The Motley Fool April 21, 2011 Brian Orelli	Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan.
The Motley Fool July 26, 2006 Brian Lawler	Biogen Slows Down Several potential growth drivers should help the biopharma. Ever since the merger with Idec, the company has been fairly well run (absent the Tysabri delays). Investors, take note.
HHMI Bulletin Aug 2011	Seeing is Believing Today, researchers are finding clever ways to deliver long-lasting, healthy genes without triggering a serious immune response.
The Motley Fool October 31, 2011 Brian Orelli	When You've Got It, You've Got It Biogen keeps its good-news streak going.
The Motley Fool October 16, 2007 Brian Lawler	Questions Surround a Biogen Deal Rumors swirl around Biogen after it publicly announces that it's for sale. Investors, take note.
The Motley Fool August 3, 2005 Charly Travers	Biotech's Big Deal The market is pleased with the partnership between Protein Design Labs and Biogen IDEC.
The Motley Fool September 14, 2006 Brian Lawler	Good Buy for Biogen Idec The biotech's past success bodes well for its plans for a new blood pressure drug. Investors, take note.
Pharmaceutical Executive February 1, 2006 Ron Feemster	Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets.
The Motley Fool January 9, 2008 Brian Lawler	Checking In on Biogen Biogen Idec presents at the JPMorgan Healthcare Conference, reiterating its long-term guidance of 15% compound annual sales growth and 20% average non-GAAP earnings-per-share growth from 2007 through 2010.
The Motley Fool January 29, 2008 Brian Lawler	Icahn Tries to Board USS Biogen Carl Icahn and the funds that he runs announce that they will try to get elected to three seats on the board of directors at Biogen Idec.
The Motley Fool March 8, 2005 Charly Travers	After the Crash, Is Biogen IDEC a Buy? Biogen stock plunge may be an overreaction to pulling multiple sclerosis drug Tysabri off the market.
The Motley Fool April 14, 2011 Frank Vinluan	Biogen Idec Inks Biotech Blood Products Research Deal With Amunix The exclusive, worldwide research collaboration agreement calls for both companies to jointly conduct preclinical research.
The Motley Fool February 7, 2008 Brian Lawler	Biogen Rests Rumors The pharmaceutical announces its year-end financial results, and squashes rumors that it is considering a major acquisition.
The Motley Fool December 20, 2007 Brian Orelli	2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something.
Bio-IT World November 12, 2002 Sue Mayer	Are Gene Patents in the Public Interest? Two recent studies from Britain argue against the unbridled patenting of genes and raise tough ethical questions.
The Motley Fool February 10, 2010 Brian Orelli	Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause.
The Motley Fool January 16, 2008 Brian Lawler	More Tysabri on the Way Biogen and Elan receive an additional approval for Tysabri. Investors, take note.
The Motley Fool May 2, 2007 Brian Lawler	Biogen's Measured Growth The biopharmaceutical reports first-quarter financial results. Investors, take note.
The Motley Fool April 25, 2008 Brian Lawler	Biogen's Big Step Forward Pharmaceutical company Biogen IDEC boasts better results and a rosier outlook.
The Motley Fool May 31, 2007 Tim Beyers	Biogen's $3 Billion Bet There are times when a buyback is not only appropriate, but also smart. This is one of those times for Biogen Idec. It's a chance for management to deliver huge returns to long-suffering shareholders.
Chemistry World October 23, 2015 Philippa Matthews	Biogen to cut 800 jobs worldwide The company will cut over 800 jobs in an effort to reduce annual operating costs by approximately $250 million.
Scientific American July 2008 Christine Soares	Looking at Yesterday's Genes for Tomorrow's Cures Resurrected "jumping gene" could deliver DNA.
The Motley Fool October 20, 2009 Brian Orelli	All Tysabri, All the Time Biogen needs to focus on its most potential-packed drug.
InternetNews August 5, 2004 Clint Boulton	Mayo Clinic to Use IBM's Blue Gene The clinic will use IBM's supercomputer to map current and historical patient records and link them to new types of medical information.
BusinessWeek March 6, 2006 Bruce Einhorn	A Cancer Treatment You Can't Get Here China, with lower regulatory hurdles, is racing to a lead in gene therapy.
The Motley Fool November 26, 2007 Brian Lawler	Biogen Plays Deal Maker Biogen Idec signs a drug development deal with Swiss-based Neurimmune Therapeutics worth up to $380 million. Investors, take note.
PC Magazine April 20, 2005 Sebastian Rupley	Speed Demon for Rent IBM is offering access to Blue Gene--the speediest of all supercomputers.
Salon.com June 1, 2000 Tabitha M. Powledge	Gene therapy R.I.P.? When the country's biggest gene therapy institute was ordered to stop testing on humans last week, the action marked the end of an era fraught with dubious claims to success and a mess of unreported adverse effects.
Reason April 2007 Ronald Bailey	Testing Your Strength The World Anti-Doping Agency is developing tests for a form of cheating that doesn't exist yet. The agency banned gene doping, the alteration of genes to enhance athletic performance.
The Motley Fool December 31, 2009 Brian Orelli	Make Money Even When Drugs Fail Biotech growth potential without as much risk can come from innovations that help drugmakers discover new drugs.
The Motley Fool July 24, 2007 Brian Lawler	Biogen's Steady Growth Biogen reports another good quarter of growth, both top- and bottom-line.
The Motley Fool May 5, 2006 Stephen D. Simpson	Biogen Idec Needs a Booster Tysabri had better come back strong, or growth could come up short for this biotech. Investors, take note.